Roberto Padilla
Psychiatric/Mental Health · El Paso, TXNPI 1912500802
Payments from drug & device makers
Across 128 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$358
- Corium, LLC$307
- AbbVie$305
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
- Alkermes, Inc.$217
- Teva Pharmaceuticals USA, Inc.$186
- plus $747 from 9 others
What the payments were for
- Food & beverage$2,27597%
- Education$713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 24 | $358 |
| Corium, LLC | 14 | $307 |
| AbbVie | 20 | $305 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $228 |
| Alkermes, Inc. | 14 | $217 |
| Teva Pharmaceuticals USA, Inc. | 6 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $154 |
| Axsome Therapeutics, Inc. | 7 | $143 |
| Otsuka America Pharmaceutical, Inc. | 7 | $122 |
| Vanda Pharmaceuticals Inc. | 6 | $100 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| Johnson & Johnson | 4 | $87 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
How this compares
$2,346 in reported general payments places this provider in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 28 | $235,862 |
| Invega SustennaPaliperidone Palmitate | 44 | $107,949 |
| AristadaAripiprazole Lauroxil | 15 | $60,566 |
| Abilify MaintenaAripiprazole | 15 | $40,566 |
| RexultiBrexpiprazole | 24 | $40,195 |
| VraylarCariprazine Hcl | 22 | $33,853 |
| Oxcarbazepine | 67 | $7,833 |
| Olanzapine | 71 | $5,212 |
| Paliperidone ErPaliperidone | 16 | $4,186 |
| Aripiprazole | 63 | $2,480 |
| Clozapine | 38 | $2,478 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 158 | $2,360 |
| Mirtazapine | 99 | $2,071 |
| Ziprasidone Hcl | 14 | $1,983 |
| Quetiapine Fumarate | 117 | $1,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $358 | $235,86228 claims |
| Johnson & JohnsonInvega Sustenna | $87 | $107,94944 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $122 | $80,76139 claims |
| Alkermes, Inc.Aristada | $217 | $60,56615 claims |
| AbbVieVraylar | $305 | $33,85322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in El Paso
- Victor IlogEl Paso$167K
- Alfredo ArellanoEl Paso$55K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.